T cell receptor alpha joining 19 (non-functional)Genealiases: []
Q-omics provides the consensus-scored TRAJ19 profile across patient tissues and cancer cell-line models. TRAJ19 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, TRAJ19 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, TRAJ19 RNA expression shows 13,400 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LGG, BRCA, and LSCC as cancer lineages where TRAJ19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ19 survival associations across molecular data types. TRAJ19 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ19 RNA expression–survival associations across cancer types. High TRAJ19 expression shows unfavorable associations in LGG, DLBC, MESO and ACC, but favorable associations in STAD and HNSC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for TRAJ19 RNA expression.
This table summarizes TRAJ19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ19 shows lower tumor expression in THCA and higher tumor expression in BRCA and KIRC. The BRCA box plot shows higher TRAJ19 RNA expression in tumor versus normal tissue (log2 FC = +0.279, t-test p = .003).
This table shows molecular features associated with TRAJ19 in patient tissues and cancer cell lines. In patient samples, TRAJ19 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
